A Phase 2 interventional study of Lenvatinib and Bevacizumab in Glioma, sponsored by Eisai Inc.. Completed at 5 sites in 2 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2022-09-29.
Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment
How we know · 6 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 851 studies in Glioma with a site in United States — 142 open to participants now, 229 under way, 6 of them phase 3. Glioma · United States.
Among the 851 studies in Glioma with a site in United States, this one is the 48th largest by enrollment of the 737 interventional ones that give a count, is one of 37 that started in 2010, is one of 227 in phase 2, and was the 277th registered.
1,454 studies on the registry are indexed under Glioma; 350 are open to participants now.
Browse Glioma studies →142 of the 851 studies in Glioma with a site in United States are open now. Recruiting first, the newest first:
Nuvation Bio Inc. · Sites in United States
Ages 18+
Children's Hospital of Philadelphia · Sites in United States
Ages 1–21
Beijing Inno Medicine Co., Ltd. · Sites in United States, China
Ages 18–70
Neonc Technologies, Inc. · Sites in United States
Ages 5–18
Children's National Research Institute · Sites in United States
Ages 3–25
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 267 Glioma studies recruiting now, 165 (62%) set no upper age limit and 56 (21%) stop at 75 or younger; 62 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
851 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 430 · Phase 2 320 · Phase 3 21 · Phase 4 6
First in 1979; this study’s year is marked. 37 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 151 is above the median of 32 across 1,076 interventional studies indexed under Glioma.
Median enrollment 30 across the 737 interventional studies, 69 across the 77 observational. Of the 564 that completed or were terminated, 203 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
172 of 851 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eisai Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
Eisai Co., Ltd. has 4 studies filed under Glioma — fewer than ten, so there is no comparison to draw.
88 of the studies in Glioma with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00978458Phase 3Eastern Cooperative Oncology GroupRadiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma | 2026-12-31 |
| NCT05271240Phase 3Northwell HealthRepeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM | 2027-04-01 |
| NCT07814872Harvard Medical School (HMS and HSDM)A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment | 2026-11 |
| NCT03510208Stanford UniversityPanitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery | 2026-11 |
| NCT05094336AmgenA Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) | 2026-11-30 |
Add all 88 to your calendar (.ics) → With an account.
Among the 851 studies in Glioma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
An open-label phase 2, multicenter study in participants with recurrent malignant glioma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All subjects who have a first or second recurrence following primary management with surgical resection or , radiotherapy and up to 2 prior systemic treatments with addition of:
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort 1 assessed participants with recurrent Grade 4 malignant glioma (ie, glioblastoma \[GBM\]) who were bevacizumab-naive. Participants were planned to be accrued in Cohort 1 and randomized in a 1:1 ratio to receive lenvatinib (experimental) or bevacizumab (active comparator). Cohort 1 - Bevacizumab Cohort 1 - Lenvatinib
Drug: Lenvatinib · Drug: Bevacizumab
Cohort 2 assessed participants with recurrent Grade 3 malignant glioma who were bevacizumab-naive. Participants in Cohort 2 were planned to be treated with lenvatinib.
Drug: Lenvatinib
Cohort 3 assessed participants with recurrent GBM who had disease progression following prior bevacizumab treatment. Participants in Cohort 3 were planned to be treated with lenvatinib.
Drug: Lenvatinib
24 mg lenvatinib capsules orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
Also known as: E7080
Bevacizumab 10 mg/kg administered intravenously every 2 weeks in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
Progression Free Survival (PFS) Rate at Month 6
PFS at Month 6 was defined as the percentage of participants who remained alive and progression-free at Month 6, based on investigator's assessment. Progression was defined using Response Assessment in Neuro-Oncology (RANO) criteria, as a greater than 25% increase in enhancing lesions despite stable or increasing steroid dose, an increase (significant) in non-enhancing T2-weighted-Fluid-Attenuated Inversion Recovery (T2/FLAIR) lesions that are not attributable to other non-tumor causes, and any new lesions. PFS rate at Month 6 was estimated from Kaplan-Meier (K-M) product-limit estimate of PFS.
Time frame: At Month 6 from randomization (Cohort 1) or first day of treatment (Cohorts 2 and 3)
Objective Response Rate (ORR)
ORR was the percentage of participants with best overall response (BOR) of complete response (CR) and partial response (PR) based on RANO criteria and investigator's assessment. CR was defined as the disappearance of all enhancing disease (measurable and non-measurable) sustained for at least 4 weeks, no new lesions, and stable or improved non-enhancing (T2/FLAIR) lesions. PR was defined as greater than or equal to 50% decrease, compared to baseline, in the sum of products of perpendicular diameters of all measureable enhancing lesions sustained for at least 4 weeks. No progression of non-measurable disease, no new lesions, stable or improved non-enhancing (T2/FLAIR) lesions on same or lower dose of corticosteroids compared to baseline. For both CR and PR, in the absence of a confirming scan 4 weeks later, this scan was considered only stable disease. Only participants with measureable disease at baseline were included in evaluation of ORR.
Time frame: From date of randomization (Cohort 1) or first day of treatment (Cohorts 2 and 3) until disease progression, development of unacceptable toxicity, withdrawal of consent or up to data cutoff date of 19 March 2013 (i.e., 2.4 years)
Progression Free Survival
PFS was measured as the time from randomization (Cohort 1) or the first day of treatment (Cohorts 2 and 3) until the date of first documentation of disease progression or date of death, if death occurred prior to disease progression, based on investigator's assessment.
Time frame: From date of randomization (Cohort 1) or first day of treatment (Cohorts 2 and 3) until disease progression, development of unacceptable toxicity, withdrawal of consent or up to data cutoff date of 19 March 2013 (ie, 2.4 years)
Overall Survival (OS)
OS was measured as the time from the randomization date (Cohort 1) or the first day of treatment (Cohort 2 and 3) to the date of death from any cause.
Time frame: From date of randomization (Cohort 1) or first day of treatment (Cohorts 2 and 3) until death due to any cause or up to data cutoff date of 19 March 2013 (ie, 2.4 years)
Disease Control Rate (DCR)
DCR was the percentage of the participants who had BOR of CR, PR, and stable disease (SD) with the minimum duration of SD lasting greater than or equal to 7 weeks. Only participants with measurable disease at baseline were included in evaluation of DCR, based on investigator's assessment.
Time frame: From date of randomization (Cohort 1) or first day of treatment (Cohorts 2 and 3) until disease progression, development of unacceptable toxicity, withdrawal of consent or up to data cutoff date of 19 March 2013 (ie, 2.4 years)
Clinical Benefit Rate (CBR)
CBR was the percentage of the participants who had BOR of CR, PR, and SD with the minimum duration of SD lasting greater than or equal to 23 weeks. Only participants with measurable disease at baseline were included in evaluation of CBR, based on investigator's assessment.
Time frame: From date of randomization (Cohort 1) or first day of treatment (Cohorts 2 and 3) until disease progression, development of unacceptable toxicity, withdrawal of consent or up to data cutoff date of 19 March 2013 (ie, 2.4 years)
Number of Participants With Adverse Events (AEs)/Serious Adverse Events (SAEs) as a Measure of Safety
Safety was assessed by monitoring and recording all AEs including all Common Terminology Criteria for Adverse Events (CTCAE) grades (for both increasing and decreasing severity) and SAEs; regular monitoring of hematology, clinical chemistry, and urine values; results of physical examinations, regular measurement of vital signs, and electrocardiograms (ECGs), as detailed in the Schedule of Visits and Procedures. The relationship of AEs to treatment was based on investigator judgment. Details of AEs and SAEs are provided in the reported adverse event section.
Time frame: For each participant, from the first patient first dose till 30 days after the last dose or the cut-off date of 19 March 2013 (ie, 2.4 years)
A total of 173 participants were screened and of those, 152 participants were deemed eligible, and 151 received study treatment.
| Milestone | Cohort 1 - Bevacizumab | Cohort 1 - Lenvatinib | Cohort 2 - Lenvatinib | Cohort 3 - Lenvatinib |
|---|---|---|---|---|
| Started | 38 | 42 | 39 | 32 |
| Treatment discontinued due to disease progression | 34 | 32 | 26 | 21 |
| Completed | 34 | 32 | 26 | 21 |
| Not completed | 4 | 10 | 13 | 11 |
| Withdrew: Adverse event | 3 | 6 | 9 | 9 |
| Withdrew: Participant choice | 0 | 2 | 2 | 0 |
| Withdrew: Withdrawal of consent | 0 | 0 | 0 | 2 |
| Withdrew: Clinical progression/deterioration | 1 | 2 | 2 | 0 |
ORR was the percentage of participants with best overall response (BOR) of complete response (CR) and partial response (PR) based on RANO criteria and investigator's assessment. CR was defined as the disappearance of all enhancing disease (measurable and non-measurable) sustained for at least 4 weeks, no new lesions, and stable or improved non-enhancing (T2/FLAIR) lesions. PR was defined as greater than or equal to 50% decrease, compared to baseline, in the sum of products of perpendicular diameters of all measureable enhancing lesions sustained for at least 4 weeks. No progression of non-measurable disease, no new lesions, stable or improved non-enhancing (T2/FLAIR) lesions on same or lower dose of corticosteroids compared to baseline. For both CR and PR, in the absence of a confirming scan 4 weeks later, this scan was considered only stable disease. Only participants with measureable disease at baseline were included in evaluation of ORR.
| Percentage of participants | Cohort 1 - Bevacizumab | Cohort 1 - Lenvatinib | Cohort 2 - Lenvatinib | Cohort 3 - Lenvatinib |
|---|---|---|---|---|
| Objective Response Rate (ORR) | 15.8 (6.0 to 31.3) | 21.4 (10.3 to 36.8) | 7.7 (1.6 to 20.9) | 0.0 (0.0 to 10.9) |
PFS was measured as the time from randomization (Cohort 1) or the first day of treatment (Cohorts 2 and 3) until the date of first documentation of disease progression or date of death, if death occurred prior to disease progression, based on investigator's assessment.
| Months | Cohort 1 - Bevacizumab | Cohort 1 - Lenvatinib | Cohort 2 - Lenvatinib | Cohort 3 - Lenvatinib |
|---|---|---|---|---|
| Progression Free Survival | 2.8 (1.9 to 3.6) | 2.4 (1.8 to 3.6) | 2.8 (1.9 to 3.7) | 1.8 (1.0 to 2.5) |
OS was measured as the time from the randomization date (Cohort 1) or the first day of treatment (Cohort 2 and 3) to the date of death from any cause.
| Months | Cohort 1 - Bevacizumab | Cohort 1 - Lenvatinib | Cohort 2 - Lenvatinib | Cohort 3 - Lenvatinib |
|---|---|---|---|---|
| Overall Survival (OS) | 6.0 (4.5 to 7.7) | 7.5 (5.6 to 11.6) | 12.0 (8.4 to NA) | 4.1 (3.0 to 5.9) |
DCR was the percentage of the participants who had BOR of CR, PR, and stable disease (SD) with the minimum duration of SD lasting greater than or equal to 7 weeks. Only participants with measurable disease at baseline were included in evaluation of DCR, based on investigator's assessment.
| Percentage of participants | Cohort 1 - Bevacizumab | Cohort 1 - Lenvatinib | Cohort 2 - Lenvatinib | Cohort 3 - Lenvatinib |
|---|---|---|---|---|
| Disease Control Rate (DCR) | 57.9 (40.8 to 73.7) | 50.0 (34.2 to 65.8) | 48.7 (32.4 to 65.2) | 28.1 (13.7 to 46.7) |
CBR was the percentage of the participants who had BOR of CR, PR, and SD with the minimum duration of SD lasting greater than or equal to 23 weeks. Only participants with measurable disease at baseline were included in evaluation of CBR, based on investigator's assessment.
| Percentage of participants | Cohort 1 - Bevacizumab | Cohort 1 - Lenvatinib | Cohort 2 - Lenvatinib | Cohort 3 - Lenvatinib |
|---|---|---|---|---|
| Clinical Benefit Rate (CBR) | 15.8 (6.0 to 31.3) | 26.2 (13.9 to 42.0) | 17.9 (7.5 to 33.5) | 6.3 (0.8 to 20.8) |
Safety was assessed by monitoring and recording all AEs including all Common Terminology Criteria for Adverse Events (CTCAE) grades (for both increasing and decreasing severity) and SAEs; regular monitoring of hematology, clinical chemistry, and urine values; results of physical examinations, regular measurement of vital signs, and electrocardiograms (ECGs), as detailed in the Schedule of Visits and Procedures. The relationship of AEs to treatment was based on investigator judgment. Details of AEs and SAEs are provided in the reported adverse event section.
| Participants | Cohort 1 - Bevacizumab | Cohort 1 - Lenvatinib | Cohort 2 - Lenvatinib | Cohort 3 - Lenvatinib |
|---|---|---|---|---|
| AEs | 38 | 40 | 39 | 32 |
| SAEs | 9 | 20 | 12 | 15 |
PFS at Month 6 was defined as the percentage of participants who remained alive and progression-free at Month 6, based on investigator's assessment. Progression was defined using Response Assessment in Neuro-Oncology (RANO) criteria, as a greater than 25% increase in enhancing lesions despite stable or increasing steroid dose, an increase (significant) in non-enhancing T2-weighted-Fluid-Attenuated Inversion Recovery (T2/FLAIR) lesions that are not attributable to other non-tumor causes, and any new lesions. PFS rate at Month 6 was estimated from Kaplan-Meier (K-M) product-limit estimate of PFS.
| Percentage of participants | Cohort 1 - Bevacizumab | Cohort 1 - Lenvatinib | Cohort 2 - Lenvatinib | Cohort 3 - Lenvatinib |
|---|---|---|---|---|
| Progression Free Survival (PFS) Rate at Month 6 | 11.0 (3.5 to 23.4) | 21.2 (10.4 to 34.5) | 8.0 (1.6 to 21.6) | 7.6 (1.3 to 21.5) |
Collected over For each participant, from the first patient first dose till 30 days after the last dose or the cut-off date of 19 March 2013 (ie, 2.4 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 - Bevacizumab | 36/38 (94.7%) | 10/38 (26.3%) | 38/38 (100%) |
| Cohort 1 - Lenvatinib | 38/42 (90.5%) | 22/42 (52.4%) | 40/42 (95.2%) |
| Cohort 2 - Lenvatinib | 27/39 (69.2%) | 12/39 (30.8%) | 39/39 (100%) |
| Cohort 3 - Lenvatinib | 30/32 (93.8%) | 15/32 (46.9%) | 31/32 (96.9%) |
| Event | Cohort 1 - Bevacizumab | Cohort 1 - Lenvatinib | Cohort 2 - Lenvatinib | Cohort 3 - Lenvatinib |
|---|---|---|---|---|
| ConvulsionNervous system disorders | 2/38 | 5/42 | 1/39 | 2/32 |
| PneumoniaInfections and infestations | 2/38 | 0/42 | 0/39 | 1/32 |
| Wound dehiscenceInjury, poisoning and procedural complications | 2/38 | 0/42 | 0/39 | 0/32 |
| FatigueGeneral disorders | 0/38 | 0/42 | 2/39 | 0/32 |
| HeadacheNervous system disorders | 0/38 | 1/42 | 2/39 | 0/32 |
| HypothyroidismEndocrine disorders | 0/38 | 2/42 | 0/39 | 0/32 |
| VomitingGastrointestinal disorders | 0/38 | 2/42 | 0/39 | 1/32 |
| General physical health deteriorationGeneral disorders | 0/38 | 2/42 | 0/39 | 0/32 |
| Cerebrovascular accidentNervous system disorders | 0/38 | 2/42 | 0/39 | 0/32 |
| Abdominal painGastrointestinal disorders | 1/38 | 0/42 | 0/39 | 1/32 |
| Event | Cohort 1 - Bevacizumab | Cohort 1 - Lenvatinib | Cohort 2 - Lenvatinib | Cohort 3 - Lenvatinib |
|---|---|---|---|---|
| FatigueGeneral disorders | 21/38 | 25/42 | 25/39 | 14/32 |
| HypertensionVascular disorders | 14/38 | 21/42 | 17/39 | 15/32 |
| HeadacheNervous system disorders | 13/38 | 6/42 | 12/39 | 13/32 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 4/38 | 14/42 | 11/39 | 9/32 |
| DiarrhoeaGastrointestinal disorders | 7/38 | 7/42 | 11/39 | 10/32 |
| ProteinuriaRenal and urinary disorders | 2/38 | 6/42 | 4/39 | 9/32 |
| NauseaGastrointestinal disorders | 10/38 | 6/42 | 8/39 | 5/32 |
| HypothyroidismEndocrine disorders | 1/38 | 7/42 | 10/39 | 4/32 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 4/38 | 8/42 | 10/39 | 4/32 |
| AphasiaNervous system disorders | 9/38 | 4/42 | 2/39 | 5/32 |
| Age, Continuous(Years) | Cohort 1 - Bevacizumab | Cohort 1 - Lenvatinib | Cohort 2 - Lenvatinib | Cohort 3 - Lenvatinib | Total |
|---|---|---|---|---|---|
| Mean | 55.1 ± 10.61 | 55.5 ± 11.96 | 49.2 ± 11.35 | 53.0 ± 11.15 | 52.6 ± 11.74 |
| Sex: Female, Male(Participants) | Cohort 1 - Bevacizumab | Cohort 1 - Lenvatinib | Cohort 2 - Lenvatinib | Cohort 3 - Lenvatinib | Total |
|---|---|---|---|---|---|
| Female | 13 | 13 | 10 | 14 | 50 |
| Male | 25 | 29 | 29 | 18 | 101 |
| World Health Organization Grading for Gliomas(Participants) | Cohort 1 - Bevacizumab | Cohort 1 - Lenvatinib | Cohort 2 - Lenvatinib | Cohort 3 - Lenvatinib | Total |
|---|---|---|---|---|---|
| Grade 3 | 0 | 0 | 39 | 0 | 39 |
| Grade 4 | 38 | 42 | 0 | 32 | 112 |
Ran from Nov 2010 to primary completion in Mar 2013, 28 months.
Results were first posted in May 2016, 3 years 2 months after primary completion.
Of 131 phase 2 interventional studies under Glioma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 88. This study's 28 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lenvatinib